BioMarin Boosts Revenue Guidance on Strong VOXZOGO Demand and Amicus Integration
Event summary
- BioMarin's Q2 2026 revenues rose 20% YoY to $990M, driven by Amicus acquisitions and VOXZOGO demand.
- VOXZOGO revenue guidance raised to at least $1B for 2026 due to strong global uptake.
- Amicus acquisition expected to deliver $280M in cost synergies by 2028, with GALAFOLD and POMBILITI + OPFOLDA targeting peak revenues of $1.4B and $1.2B respectively by mid-2030s.
- FDA accepted sNDA for VOXZOGO in achondroplasia with PDUFA target date of February 28, 2027.
The big picture
BioMarin's strategic shift towards rare disease biotechnology is accelerating with the Amicus acquisition, positioning it to capture significant market share in high-growth therapeutic areas. The integration of GALAFOLD and POMBILITI + OPFOLDA into its portfolio aligns with industry trends toward targeted therapies for genetically defined conditions. Success will depend on executing cost synergies while maintaining innovation momentum.
What we're watching
- Integration Success
- Whether BioMarin can fully realize the $280M in cost synergies from the Amicus acquisition by 2028.
- Regulatory Approvals
- The timeline and outcome of FDA decisions on VOXZOGO for hypochondroplasia and achondroplasia.
- Revenue Diversification
- How the combined portfolio will perform in terms of revenue growth and operating margin expansion through 2030s.
Related topics